http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#Head http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#provenance http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#pubinfo http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion http://purl.obolibrary.org/obo/DOID_9952 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9952 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00631 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association http://www.w3.org/2000/01/rdf-schema#label clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in disease related symptoms or increased survival with clofarabine injection clofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in disease related symptoms or increased survival with clofarabine injection 1 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00631 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#provenance http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#pubinfo http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig http://purl.org/nanopub/x/hasSignature B3GI2fl6Y1C4IFz15oqvnEqoK3QBdX1j67sMJoaQy8iButSKBFxfrO3KqJEvixtA9YY2h+hWM3Wd3JMFCHTZJPASmGhixMas0g5vm0X5Kh2bKQ7EYCas2Kku5irrF2gynNByptcJuWfPqy0HUQLCVL1iROwUC2ySFtye1rwixyM= http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://purl.org/dc/terms/created 2021-06-29T08:38:39.855+02:00 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs